ゴーシェ病の世界市場レポート 2025年

ゴーシェ病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で22億1,000万米ドルに成長します。予測期間の成長は、次世代治療、世界の患者登録の拡大、治療へのアクセス改善、個別化医療アプローチ、希少疾患に対する規制支援などに起因すると考えられます。予測期間の世界の動向には、治療モニタリングにおける技術革新、研究における国際協力、経口治療薬の進歩、新生児スクリーニングプログラムの拡大、患者アクセスのための世界的協力などが含まれます。

遺伝子異常の有病率の増加は、今後数年間のゴーシェ病市場の成長を牽引すると予想されます。遺伝子異常とは、個人の遺伝子のDNA配列に変化や変異が生じ、それが異常な特徴や機能、特性につながることを指します。ゴーシェ病は常染色体劣性遺伝であるため、発症するには変異したGBA遺伝子を両親から2つずつ受け継ぐ必要があります。ゴーシェ病を持つ人は、特定の酵素が十分に生産されないため、脾臓や肝臓などの特定の臓器に脂質として知られる脂肪物質が蓄積します。例えば、米国を拠点とする非営利団体Cystic Fibrosis Foundationは、2023年、肺移植を行わない嚢胞性線維症の総人口は2022年に31,171人であったが、2023年には31,752人に増加したと報告しています。このように、遺伝子異常の有病率の増加がゴーシェ病市場の成長に拍車をかけています。

ゴーシェ病市場の成長は、臨床試験数の増加によって促進されると予想されます。臨床試験は、ヒトが参加し、新しい治療、介入、薬剤の安全性と有効性を評価するものです。ゴーシェ病における臨床試験の増加は、治療の進歩、疾患理解の向上、診断とスクリーニングの改善、個別化医療の開発につながる可能性があります。2023年5月のXtalksによると、452,604件の臨床試験が登録されており、64,838件が積極的に参加者を求めています。これは2021年の登録試験数365,000件から大幅に増加しており、ゴーシェ病市場の成長に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ゴーシェ病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のゴーシェ病市場：成長率分析
• 世界のゴーシェ病市場の実績：規模と成長, 2019-2024
• 世界のゴーシェ病市場の予測：規模と成長, 2024-2029, 2034F
• 世界ゴーシェ病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のゴーシェ病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゴーシェ病1型
• ゴーシェ病2型
• ゴーシェ病3型
• その他のタイプ
• 世界のゴーシェ病市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• 血液検査
• 画像検査
• 妊娠前スクリーニングと出生前検査
• その他の診断
• 世界のゴーシェ病市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法
• 基質還元療法
• 世界のゴーシェ病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のゴーシェ病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界のゴーシェ病市場、ゴーシェ病1型のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法（ERT）
• 基質還元療法（SRT）
• 世界のゴーシェ病市場、ゴーシェ病2型のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 支持療法
• 実験的治療法
• 世界のゴーシェ病市場、ゴーシェ病3型のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法（ERT）
• 症状管理
• 世界のゴーシェ病市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゴーシェ病の稀な変異
• 関連症候群

第7章 地域別・国別分析

• 世界のゴーシェ病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のゴーシェ病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ゴーシェ病市場：競合情勢
• ゴーシェ病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Moderna Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• BioMarin Pharmaceutical Inc.
• CHIESI Farmaceutici SPA
• IntraBio Inc.
• REGENXBIO Inc.
• JCR Pharmaceuticals Co. Ltd.
• Ultragenyx Pharmaceutical Inc.
• Amicus Therapeutics Inc.
• Pharming Group N.V.
• Idorsia Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ゴーシェ病市場2029：新たな機会を提供する国
• ゴーシェ病市場2029：新たな機会を提供するセグメント
• ゴーシェ病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gaucher's disease, a rare genetic disorder, disrupts the metabolism of a specific type of fat known as glucocerebroside. The disorder arises from the accumulation of a fatty substance called glucocerebroside within certain cells, particularly in the spleen, liver, bone marrow, and sometimes in the brain.

The primary categories of Gaucher's disease encompass Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. Gaucher disease type 1, the most prevalent form, is distinguished by a deficiency of the enzyme glucocerebrosidase. The diverse diagnostic methods include physical examinations, blood tests, imaging tests, preconception screening, prenatal testing, and others. Treatment options involve enzyme replacement therapy and substrate reduction therapy, which can be administered through oral, parenteral, and various other routes by end users such as hospitals, specialty clinics, homecare, and others.

The Gaucher's disease market research report is one of a series of new reports from The Business Research Company that provides Gaucher's disease market statistics, including the Gaucher's disease industry global market size, regional shares, competitors with Gaucher's disease market share, detailed Gaucher's disease market segments, market trends and opportunities, and any further data you may need to thrive in the Gaucher's disease industry. This Gaucher's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gaucher's disease market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to enzyme replacement therapy (ert) development, increasing disease awareness, genetic research and diagnosis, patient advocacy initiatives, government incentives for rare diseases.

The gaucher's disease market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to next-generation therapies, global patient registry expansion, improvements in access to treatment, personalized medicine approaches, regulatory support for rare diseases. Major trends in the forecast period include technological innovations in treatment monitoring, international collaborations in research, oral therapeutics advancements, expanded newborn screening programs, global collaboration for patient access.

The increasing prevalence of genetic abnormalities is anticipated to drive the growth of the Gaucher's disease market in the coming years. Genetic abnormalities refer to changes or mutations in the DNA sequence of an individual's genes that can lead to abnormal features, functions, or characteristics. Gaucher's disease follows an autosomal recessive inheritance pattern, meaning that a person must inherit two copies of the mutated GBA gene, one from each parent, to develop the condition. Individuals with Gaucher's disease do not produce enough of a specific enzyme, resulting in the accumulation of fatty substances known as lipids in certain organs, such as the spleen and liver. For example, in 2023, the Cystic Fibrosis Foundation, a US-based non-profit organization, reported that the total population with cystic fibrosis without lung transplants was 31,171 in 2022 and rose to 31,752 in 2023. Thus, the increasing prevalence of genetic abnormalities is fueling the growth of the Gaucher's disease market.

The growth of the Gaucher's disease market is expected to be fueled by the rising number of clinical trials. Clinical trials, involving human participants, evaluate the safety and efficacy of new medical treatments, interventions, or drugs. Increased clinical trials in Gaucher's disease can lead to advancements in treatment, better disease understanding, improved diagnosis and screening, and the potential development of personalized medicine. According to Xtalks in May 2023, there are 452,604 registered clinical studies, with 64,838 actively seeking participants. This marks a substantial increase from the 365,000 registered trials in 2021, contributing significantly to the growth of the Gaucher's disease market.

Major companies in the Gaucher's disease market are adopting innovative technologies such as next-generation sequencing (NGS) to enhance patient care. NGS, a high-throughput sequencing technology, enables rapid and cost-effective DNA and RNA sequencing. For instance, Eurofins Genomics LLC launched a whole plasmid sequencing service utilizing advanced Gen3 NGS technology, offering same-day results with up to 99% single-base accuracy. This service, accommodating DNA constructs from 2.5 to 300 kb, combines the accuracy and quick turnaround of Sanger sequencing with NGS's comprehensive analysis capabilities, providing a cost-effective and time-efficient solution for genetic analysis.

Key companies in the Gaucher disease market are concentrating on developing innovative solutions such as AAV gene therapy, aimed at providing a groundbreaking, one-time treatment for Gaucher disease Type 1. Adeno-associated virus (AAV) gene therapy utilizes AAV vectors to deliver therapeutic genes to cells, thereby correcting disease-causing mutations. For example, in January 2022, Freeline Therapeutics Holdings plc, a UK-based biotechnology firm, announced that the US FDA approved FLT201 for Gaucher disease Type 1. FLT201 employs an advanced AAVS3 capsid paired with a liver-specific promoter to deliver a novel glucocerebrosidase variant (GCasevar85). This FDA-cleared IND represents the first AAV-mediated gene therapy to enter clinical trials for Gaucher disease Type 1, underscoring its potential to provide a new therapeutic option for patients.

Major companies operating in the gaucher's disease market report are Pfizer Inc., Johnson & Johnson, Merck and Co. Inc., Novartis AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Moderna Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., CHIESI Farmaceutici SPA, IntraBio Inc., REGENXBIO Inc., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Pharming Group N.V., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, AVROBIO Inc., Resverlogix Corp., GenSight Biologics S.A., ISU Abxis Co. Ltd., SIRION BIOTECH GmbH, Greenovation Biotech GmbH, Orphazyme A/S

North America was the largest region in the Gaucher's disease market in 2024. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gaucher's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gaucher's disease market includes revenues earned by entities by providing services such as genetic counseling, patient education and support, research and clinical trials, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The gaucher's disease market consists of sales of bone health supplements, medical equipment, and diagnostic testing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gaucher's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gaucher's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gaucher's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gaucher's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Gaucher Disease Type 1; Gaucher Disease Type 2; Gaucher Disease Type 3; Other Types
• 2) By Diagnosis: Physical Exam; Blood Tests; Imaging Tests; Preconception Screening And Prenatal Testing; Other Diagnoses
• 3) By Therapy: Enzyme Replacement Therapy; Substrate Reduction Therapy
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Gaucher Disease Type 1: Enzyme Replacement Therapy (ERT); Substrate Reduction Therapy (SRT)
• 2) By Gaucher Disease Type 2: Supportive Care; Experimental Therapies
• 3) By Gaucher Disease Type 3: Enzyme Replacement Therapy (ERT); Symptomatic Management
• 4) By Other Types: Rare Variants Of Gaucher Disease; Related Syndromes
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck and Co. Inc.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gaucher's Disease Market Characteristics

3. Gaucher's Disease Market Trends And Strategies

4. Gaucher's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Gaucher's Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gaucher's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gaucher's Disease Market Growth Rate Analysis
• 5.4. Global Gaucher's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gaucher's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gaucher's Disease Total Addressable Market (TAM)

6. Gaucher's Disease Market Segmentation

• 6.1. Global Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gaucher Disease Type 1
• Gaucher Disease Type 2
• Gaucher Disease Type 3
• Other Types
• 6.2. Global Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Exam
• Blood Tests
• Imaging Tests
• Preconception Screening And Prenatal Testing
• Other Diagnoses
• 6.3. Global Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Substrate Reduction Therapy
• 6.4. Global Gaucher's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Gaucher's Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.6. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• 6.7. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Experimental Therapies
• 6.8. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy (ERT)
• Symptomatic Management
• 6.9. Global Gaucher's Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Variants Of Gaucher Disease
• Related Syndromes

7. Gaucher's Disease Market Regional And Country Analysis

• 7.1. Global Gaucher's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gaucher's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gaucher's Disease Market

• 8.1. Asia-Pacific Gaucher's Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gaucher's Disease Market

• 9.1. China Gaucher's Disease Market Overview
• 9.2. China Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gaucher's Disease Market

• 10.1. India Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gaucher's Disease Market

• 11.1. Japan Gaucher's Disease Market Overview
• 11.2. Japan Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gaucher's Disease Market

• 12.1. Australia Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gaucher's Disease Market

• 13.1. Indonesia Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gaucher's Disease Market

• 14.1. South Korea Gaucher's Disease Market Overview
• 14.2. South Korea Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gaucher's Disease Market

• 15.1. Western Europe Gaucher's Disease Market Overview
• 15.2. Western Europe Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gaucher's Disease Market

• 16.1. UK Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gaucher's Disease Market

• 17.1. Germany Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gaucher's Disease Market

• 18.1. France Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gaucher's Disease Market

• 19.1. Italy Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gaucher's Disease Market

• 20.1. Spain Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gaucher's Disease Market

• 21.1. Eastern Europe Gaucher's Disease Market Overview
• 21.2. Eastern Europe Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gaucher's Disease Market

• 22.1. Russia Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gaucher's Disease Market

• 23.1. North America Gaucher's Disease Market Overview
• 23.2. North America Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gaucher's Disease Market

• 24.1. USA Gaucher's Disease Market Overview
• 24.2. USA Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gaucher's Disease Market

• 25.1. Canada Gaucher's Disease Market Overview
• 25.2. Canada Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gaucher's Disease Market

• 26.1. South America Gaucher's Disease Market Overview
• 26.2. South America Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gaucher's Disease Market

• 27.1. Brazil Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gaucher's Disease Market

• 28.1. Middle East Gaucher's Disease Market Overview
• 28.2. Middle East Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gaucher's Disease Market

• 29.1. Africa Gaucher's Disease Market Overview
• 29.2. Africa Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gaucher's Disease Market Competitive Landscape And Company Profiles

• 30.1. Gaucher's Disease Market Competitive Landscape
• 30.2. Gaucher's Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Gaucher's Disease Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Moderna Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. BioMarin Pharmaceutical Inc.
• 31.8. CHIESI Farmaceutici SPA
• 31.9. IntraBio Inc.
• 31.10. REGENXBIO Inc.
• 31.11. JCR Pharmaceuticals Co. Ltd.
• 31.12. Ultragenyx Pharmaceutical Inc.
• 31.13. Amicus Therapeutics Inc.
• 31.14. Pharming Group N.V.
• 31.15. Idorsia Pharmaceuticals Ltd.

32. Global Gaucher's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gaucher's Disease Market

34. Recent Developments In The Gaucher's Disease Market

35. Gaucher's Disease Market High Potential Countries, Segments and Strategies

• 35.1 Gaucher's Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gaucher's Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gaucher's Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer